Volume 24, Number 3—March 2018
Use of Verbal Autopsy to Determine Underlying Cause of Death during Treatment of Multidrug-Resistant Tuberculosis, India
Mycobacterium tuberculosis resistant to >2 of the most potent TB drugs, isoniazid and rifampin, is classified as multidrug-resistant tuberculosis (MDR TB). Worldwide, an estimated 580,000 MDR TB cases emerge annually (1). Unfortunately, there are substantial gaps in MDR TB detection and treatment. Approximately 1 of 5 persons needing MDR TB treatment actually receive it, and among those who do receive treatment, less than half (48%) who start treatment finish successfully (1,2). These rates are driven by treatment failure, loss to follow-up, and premature death. In 2016, the proportion of deaths during MDR TB treatment in India was higher than the global average (20% vs. 14%) (3).
India follows the routine surveillance and reporting guidelines recommended by the World Health Organization (WHO) and considers any death that occurs during TB treatment as a TB-related death. Several studies have used all-cause mortality as a surrogate marker of mortality attributable to TB (4–6). This method of attributing all-cause mortality can overestimate TB case-fatality rates. Accurately determining the cause of death is the first step to designing appropriate and timely interventions to prevent premature deaths.
In settings with no or poorly documented vital registration and medical certification of the cause of death, verbal autopsy can be an essential public health tool for obtaining a reasonable estimation of the cause structure of mortality (7). Verbal autopsy uses systematic retrospective inquiry of family members about the symptoms and signs of illness before death to help determine the putative medical cause of death (8). The demand for and use of verbal autopsy data has rapidly gained importance and has been used to set global health priorities (9,10). Verbal autopsy data may improve surveillance and program monitoring and evaluation and could stimulate change in public health policy (11–13). In our study, we used the verbal autopsy method to determine the underlying causes of death for persons who died during MDR TB treatment (Technical Appendix[PDF - 391 KB - 6 pages]).
Study Design and Population
We conducted a cross-sectional study of patients who died during MDR TB treatment during January–December 2016 at 3 drug-resistant TB (DR-TB) treatment centers in southwestern Karnataka state in India (Figure). The DR-TB centers serve 3 major populations of Karnataka (Bangalore, 17.9 million persons from 7 districts; Mangalore, 4.6 million persons from 3 districts; and Mysore, 10.1 million persons from 6 districts) (3). DR-TB centers, established with the support of Revised National Tuberculosis Control Program of India (RNTCP), are located within tertiary care centers, public hospitals, and teaching hospitals and follow national guidelines for the treatment of drug-resistant TB (2). The study participants included family proxies of deceased patients. For the purpose of data collection, family proxies included spouses, parents, adult children, siblings, or relatives involved in providing care to the deceased person.
MDR TB patients were started on a standardized second-line treatment regimen at DR-TB centers followed by ambulatory care in the community. Pretreatment clinical evaluations were required; these included chest radiograph; complete hemogram; liver, renal and thyroid function tests; HIV serology; screening for diabetes mellitus; calculation of body mass index; and for women, pregnancy tests. All patients were required to complete >7 days of inpatient treatment at DR-TB centers, where they began treatment for MDR TB in accordance with national guidelines (i.e., 6 months of kanamycin, levofloxacin, ethionamide, pyrazinamide, ethambutol, and cycloserine followed by 18 months of levofloxacin, ethionamide, ethambutol, and cycloserine). Patients who did not achieve culture conversion at 6 months, or who experienced culture reversion at any time during treatment, were considered to have poor treatment response and required reevaluation and second-line drug susceptibility testing. Throughout treatment, community-based directly observed treatment (DOT) providers monitored patients for adverse drug effects. DOT providers referred patients experiencing any major adverse drug reactions to appropriate health facilities. The management of existing comorbidities such as diabetes, liver or renal disease, and neurological or psychiatric disorders is also recommended by the RNTCP (2).
In accordance with national policy, district TB officers should conduct an audit for all deaths occurring among MDR TB patients to better understand potential programmatic gaps in TB diagnosis and treatment (2). However, TB death audits do not look into the underlying cause of death.
We developed a semistructured questionnaire as a verbal autopsy tool to elicit information about behavioral, demographic, socioeconomic, and comorbid conditions; detailed symptoms; and chronology of events preceding death, with the most recent condition first and the earliest (e.g., the condition that started the sequence of events between normal health and death) last. We also abstracted relevant clinical information from medical records and, when available from the family, the cause of death as documented on a death certificate. We abstracted the information on date of death and the date of initiation of treatment from programmatic management of drug-resistant TB treatment cards to calculate the median duration of MDR TB treatment. A committee of 3 clinicians independently reviewed all available evidence to ascertain the underlying cause of death following national guidelines (14). A final assignment of the cause of death required the concurrence of >2 committee members. If 2 reviewers did not concur on cause of death, then they would meet in person to discuss their disagreement. The committee assigned the underlying cause of death as TB if it had initiated the sequence of illness events leading directly to death (14). If the underlying cause of death was not TB, then the committee also recorded what was believed to be the specific cause of death using codes from the International Classifications of Diseases, 10th Revision, as recommended by WHO (15). For patients with a cause of death not directly attributed to TB but that may have resulted from TB or TB treatment (e.g., drug-induced psychosis leading to suicide), we listed TB as an underlying cause of death.
We conducted proxy interviews during December 2016–March 2017. The principal investigator, who had prior experience in conducting verbal autopsy, trained a team of investigators to obtain clinical histories and document the sequence of events preceding death using the verbal autopsy tool. The field investigators prepared participants psychologically for the verbal autopsy process and provided appropriate grief counseling when needed. The principal investigator supervised the field investigators to ensure correct protocol implementation, made home visits to identify potential challenges, provided feedback, and recommended corrective action to ensure quality data collection.
Families with an annual income <10,000 Indian rupees are eligible for government supplemental support with Below Poverty Line (BPL) ration cards (16). We used BPL cards as a proxy for socioeconomic status of the families.
We included history of smoking and alcohol consumption of the deceased person in the proxy questionnaire. We did not quantify the number of cigarettes smoked, nor the amount of alcohol consumed, because these details were deemed not accurate through proxy.
We used EpiData (EpiData Association, Odense, Denmark) to double enter, validate, and analyze quantitative data. We calculated simple proportions of selected demographic, behavioral, and clinical characteristics among cases with and without TB as the underlying cause. We used the χ2 test to detect differences in proportions among cases with and without TB as the underlying cause of death and the Fisher exact test when individual cell counts were <5 (α<0.05). We calculated the duration of MDR TB treatment as the number of days from date of initiation of treatment to date of death. We abstracted missed doses of TB drugs from treatment cards and used medians and interquartile ranges (IQRs) to describe the number of doses missed and duration of MDR TB treatment. We compared medians between cases with and without TB as the underlying cause of death using a Mann-Whitney test.
We obtained approval for the study protocol from the Yenepoya University Ethics Committee (Mangalore, India); Ethics Advisory Group of International Union Against Tuberculosis and Lung Disease (Paris, France); National Tuberculosis Institute (Bangalore, India); and US Centers for Disease Control and Prevention (Atlanta, GA, USA). We conducted proxy consent and verbal autopsies in the local language, Kannada. We ensured strict privacy and confidentiality during all participant encounters. All interviews occurred at participants’ homes at a time convenient to them. Institutional-, district-, and state-level authorities granted appropriate permission before initiating the study.
A total of 75 TB-related deaths occurred during the study period. For these, 72 family proxies (96%) consented to verbal autopsy. Most of the proxies were the spouse of the deceased (37%), followed by parents (16%), adult children (16%), siblings (16%), in-laws (10%), and other relatives (5%). In addition to verbal autopsy data available for 72 of the deceased patients, medical records for 8 patients were available from the family, and 4 patients had death certificates that their proxies provided during interviews. The death audit report was available for 2 patients.
The committee reviewed all available data and independently and unanimously assigned TB as the underlying cause of death for 49 (68%) patients. For the remaining 23 patients, the committee reached consensus after face-to-face deliberation (Table 1). The committee members assigned the underlying cause of death for 71 out of 72 patients. For 1 patient, there was insufficient evidence to assign a specific cause of death; we excluded this patient from further analysis. TB was the underlying cause for 77% (55/71) of the deaths (Table 2) (14). After extensive deliberations and discussions, the committee deemed TB or TB treatment the underlying cause of death for 6 patients who died of suicide. Suicidal ideation may be associated with TB because of psychological stress, social stigma, hopelessness, and depression caused by MDR TB diagnosis or treatment; in addition, cycloserine used to treat MDR TB may have caused psychosis or depression resulting in suicidal ideations (17,18). For 2 patients who died of pulmonary embolism, the committee decided that immobilization related to severe MDR TB disease predisposed them to pulmonary embolism and increased their risk of death.
We described the characteristics of the 71 MDR TB patients who died during treatment by underlying cause of death (Table 3). The mean age of the patients was 44 years (SD ± 14 years), and more than two thirds (69%) were male. Deaths with TB as the underlying cause were significantly less common (p = 0.011) among male patients (Table 3). The median (IQR) duration of treatment for patients with TB as underlying cause of death was 192 (101–365) days and for those without was 158 (76–459) days. The median (IQR) number of missed TB doses for patients with TB as underlying cause of death was 24 (6–60) and for those without was 20 (9–46). We saw no significant differences in the duration of treatment (p = 0.50) or the number of missed doses (p = 0.16) between patients with TB as underlying cause of death and those without.
Our methods were consistent with the current national policy in India of conducting death audits by public health authorities to ascertain the cause of death and identify gaps in program implementation (19). We were not aware of previous reports of using verbal autopsy to ascertain the underlying cause of death among patients treated for MDR TB in India. Death rates among MDR TB patients treated in Maharashtra and Western India ranged 21%–30% (20,21). These reports defined TB-related deaths in accordance with the RNTCP treatment outcome variable (i.e., all-cause mortality) and may not reflect the true estimate of deaths attributable to TB. A recent study among a smaller cohort of HIV-infected MDR TB patients treated in Mumbai reported 4 (31%) of 13 deaths were attributed to causes not related to TB or treatment (22). These data suggest that the RNTCP may be overestimating TB-related deaths among MDR TB patients. In our study, we found that 23% (16/71) of patients who died during MDR TB treatment did not have TB as an underlying cause of death.
Our study had several strengths. We identified all TB patients in the national control program who died during the study period and had a high proxy response rate (96%). Therefore, selection bias was unlikely. In contrast to using the death audit method, which is not well-defined (19), we systematically gathered the medical history of patients who had died by interviewing key informants and reviewing medical records and death certificates. These additional sources of information increased the total data available for each case that might otherwise be missed by reviewing medical records alone. Furthermore, we constituted an independent committee of medical specialists not affiliated with RNTCP to review all the available evidence and code the underlying causes of death, which reduced bias that may occur when TB program personnel conduct a death audit. Consensus among committee members increased the validity of our results. In addition, causes of death secondary to TB, such as treatment-related suicide and pulmonary embolism (23), enriched the qualitative aspects of TB-related deaths that could otherwise be missed.
Our study had some limitations. In India, as many as 2 million TB patients seek care in the largely unregulated private sector (24). We included only patients who received treatment from the national TB control program; thus, our study findings do not reflect all MDR TB patients in India. Unlike the RNTCP death audit, which focuses on identifying potential gaps in program implementation (19), our study focused only on ascertaining the medical cause of death. Therefore, we are unable to comment on the potential gaps in program implementation that may have precipitated death. Furthermore, as with all verbal autopsy studies, the robustness of the results depends on the accuracy of the information provided by key informants. We worked to minimize errors by following standard procedures, but it is possible that some errors may have occurred. We did not collect information on whether the deceased patients had undergone drug susceptibility testing for the second-line TB drugs and so are unable to comment if persons with more severe forms of TB disease were more likely to die of TB than those with less severe forms of TB.
Despite these limitations, the study has several implications for policy and practice. First, a substantial proportion of deaths during MDR TB treatment were not TB related. Our results suggest the national TB program may be overestimating TB case-fatality rates. Incorporating verbal autopsies as part of the death audit may help improve the accuracy of defining TB-related deaths. Second, suicide was common (n = 6) and attributed as secondary to TB disease or treatment of TB. These deaths were potentially preventable. Cycloserine is known to lead to psychiatric adverse reactions, including suicidal tendencies (2,17). WHO recently recommended that cycloserine be replaced with other oral second-line drugs (25). In addition, 4 patients had alcohol-related deaths. While these deaths were not considered secondary to TB, it is unclear if these patients also had depression. A population-based study in Kerala reported higher risk for poor treatment outcome, including death, among MDR TB patients consuming alcohol (26). These data reinforce the need for professional counseling and psychiatric care integration for MDR TB care (2). A recent study assessed the feasibility of integrated psychiatric and medical TB care and treatment and suggested the immediate need in India (27). Third, our finding that male sex was associated with deaths due to causes other than TB may be helpful in generating hypotheses for further research, such as risk-factor analysis in a larger, more representative cohort of patients throughout India. Finally, we acknowledge that many TB-related deaths may occur before the start of MDR treatment, after completion of MDR treatment, and among persons lost to follow-up. We are hopeful our findings will stimulate further research to document all potential TB-related deaths in the community and aid in monitoring India’s progress toward reducing TB deaths by 95% by 2035 (28).
Dr. Naik is a professor in the Department of Community Medicine, Yenepoya Medical College, Mangalore, and deputy director of the Directorate of Rural Health Care and Development, Yenepoya University. Her primary research interests include tuberculosis, noncommunicable diseases, health system research, and adolescent health.
We thank all of the proxies and families who had the courage to participate in our research during a time of mourning, grief, and personal loss. We thank the state TB officer, district TB officers, and program staff of the districts and DR-TB centers who facilitated this study. We are indebted to our independent committee members for their time and expertise during the verbal autopsy review and deliberation: Prabha Adhikari, K.M. Akshaya, Deepu Chengappa. Special thanks to Viquar Ahmed, K.R. Nischith, and Reshma Acharya for their assistance with data acquisition and local coordination and to James Tobias for cartographic assistance.
The study was conducted as a part of the National Operational Research Training Course, 2016. This training project was conceived and implemented jointly by Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India; the National TB Institute, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India Bangalore, India; the International Union Against Tuberculosis and Lung Diseases, South-East Asia Regional Office, New Delhi, India; and the Division of Global HIV and TB, Center for Global Health, US Centers for Disease Control and Prevention. This study was funded by the International Union Against Tuberculosis and Lung Diseases (South-East Asia Regional Office, New Delhi, India). The travel costs associated with data collection were funded by Yenepoya University, Mangalore, Karnataka, India.
Author contributions: study conception and design, P.R.N., P.K.M., A.S.N., H.D.S., M.P., and S.S.; data collection and data entry, P.R.N., A.S.N., P.R., H.D.S.; data analysis and interpretation, P.R.N., A.S.N., P.K.M., S.S., H.D.S., P.R., C.R.; article first draft, P.R.N., P.K.M., S.S., H.D.S., A.S.N., R.C., A.S., M.P. All authors provided critical comments and approval of the final article.
- World Health Organization. Global tuberculosis report. Geneva: The Organization; 2016 [cited 2017 Jul 24]. http://www.who.int/tb/publications/global_report/en/
- Central Tuberculosis Division, Directorate General of Health Services, Ministry of Health and Family Welfare. Guidelines on programmatic management of drug resistant TB (PMDT) in India. New Delhi: The Directorate; 2012 [cited 2017 Jul 24]. https://tbcindia.gov.in/WriteReadData/l892/8320929355Guidelines%20for%20PMDT%20in%20India%20-%20May%202012.pdf
- Central Tuberculosis Division, Directorate General of Health Services. TB India 2017, Revised National TB Control Programme, annual status report. New Delhi: The Directorate; 2016 [cited 2017 Jul 24]. https://tbcindia.gov.in/WriteReadData/TB%20India%202017.pdf
- Lin CH, Lin CJ, Kuo YW, Wang JY, Hsu CL, Chen JM, et al. Tuberculosis mortality: patient characteristics and causes. BMC Infect Dis. 2014;14:5.
- Rao VK, Iademarco EP, Fraser VJ, Kollef MH. The impact of comorbidity on mortality following in-hospital diagnosis of tuberculosis. Chest. 1998;114:1244–52.
- Hansel NN, Merriman B, Haponik EF, Diette GB. Hospitalizations for tuberculosis in the United States in 2000: predictors of in-hospital mortality. Chest. 2004;126:1079–86.
- World Health Organization. Verbal autopsy standards: The 2012 WHO verbal autopsy instrument. Geneva: The Organization; 2012 [cited 2017 Jun 28]. http://www.who.int/healthinfo/statistics/WHO_VA_2012_RC1_Instrument.pdf
- Indian Council of Medical Research. Study on causes of death by verbal autopsy in India. New Delhi: The Council; 2009 [cited 2017 Jul 24]. http://www.icmr.nic.in/final/causes_death/Contents%20NCD.pdf
- Setel PW, Sankoh O, Rao C, Velkoff VA, Mathers C, Gonghuan Y, et al. Sample registration of vital events with verbal autopsy: a renewed commitment to measuring and monitoring vital statistics. Bull World Health Organ. 2005;83:611–7.
- Lopez AD. Counting the dead in China. Measuring tobacco’s impact in the developing world. BMJ. 1998;317:1399–400.
- Murray CJL, Lozano R, Flaxman AD, Serina P, Phillips D, Stewart A, et al. Using verbal autopsy to measure causes of death: the comparative performance of existing methods. BMC Med. 2014;12:5.
- Palanivel C, Yadav K, Gupta V, Rai SK, Misra P, Krishnan A. Causes of death in rural adult population of North India (2002-2007), using verbal autopsy tool. Indian J Public Health. 2013;57:78–83.
- Jha P. Reliable direct measurement of causes of death in low- and middle-income countries. BMC Med. 2014;12:19.
- World Health Organization. Medical certification of cause of death. Geneva: The Organization; 1979 [cited 2017 Jul 24]. http://apps.who.int/iris/bitstream/10665/40557/1/9241560622.pdf
- Centers for Medicaid and Medicare Services. ICD-10-CM tabular list of diseases and injuries 2010 [cited 2017 Jul 24]. https://www.cms.gov/medicare/coding/icd10/downloads/6_i10tab2010.pdf
- RationCardGov.in. Ration card—types and uses [cited 2017 Jul 24]. http://rationcardgov.in/ration-card-types/
- Behera C, Krishna K, Singh HR. Antitubercular drug–induced violent suicide of a hospitalised patient. BMJ Case Rep. 2014;2014:bcr2013201469.
- Vega P, Sweetland A, Acha J, Castillo H, Guerra D, Smith Fawzi MC, et al. Psychiatric issues in the management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2004;8:749–59.
- Central Tuberculosis Division, Directorate General of Health Services, Ministry of Health and Family Welfare. Revised National TB Control Programme in India. Technical and operational guidelines for tuberculosis control in India. New Delhi: The Directorate; 2016 [cited 2017 Jul 24]. https://tbcindia.gov.in/WriteReadData/TOG.zip
- Suryawanshi SL, Shewade HD, Nagaraja SB, Nair SA, Parmar M. Unfavourable outcomes among patients with MDR-TB on the standard 24-month regimen in Maharashtra, India. Public Health Action. 2017;7:116–22.
- Patel SV, Nimavat KB, Alpesh PB, Shukla LK, Shringarpure KS, Mehta KG, et al. Treatment outcome among cases of multidrug-resistant tuberculosis (MDR TB) in Western India: A prospective study. J Infect Public Health. 2016;9:478–84.
- Isaakidis P, Cox HS, Varghese B, Montaldo C, Da Silva E, Mansoor H, et al. Ambulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, India. PLoS One. 2011;6:e28066.
- Gupta A, Mrigpuri P, Faye A, Bandyopadhyay D, Singla R. Pulmonary tuberculosis - An emerging risk factor for venous thromboembolism: A case series and review of literature. Lung India. 2017;34:65–9.
- Arinaminpathy N, Batra D, Khaparde S, Vualnam T, Maheshwari N, Sharma L, et al. The number of privately treated tuberculosis cases in India: an estimation from drug sales data. Lancet Infect Dis. 2016;16:1255–60.
- World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis—2016 update. Geneva: The Organization; 2016 [cited 2017 July 24]. http://apps.who.int/iris/bitstream/10665/250125/1/9789241549639-eng.pdf
- Duraisamy K, Mrithyunjayan S, Ghosh S, Nair SA, Balakrishnan S, Subramoniapillai J, et al. Does Alcohol consumption during multidrug-resistant tuberculosis treatment affect outcome? A population-based study in Kerala, India. Ann Am Thorac Soc. 2014;11:712–8.
- Thomas B, Suhadev M, Mani J, Ganapathy BG, Armugam A, Faizunnisha F, et al. Feasibility of an alcohol intervention programme for TB patients with alcohol use disorder (AUD)—a qualitative study from Chennai, South India. PLoS One. 2011;6:e27752.
- World Health Organization. WHO End TB strategy. Geneva: The Organization; 2015 [cited 2017 July 24]. http://www.who.int/tb/post2015_strategy/en/